Immunocore gets EU nod for TCR cancer therapy Kimmtrak
pharmaphorum
APRIL 5, 2022
Uveal melanoma is a rare cancer of the eye, which in the majority of patients is localised. It’s the first treatment for mUM in the EU, as well as the first BiTE drug to treat a solid tumour. However, when it becomes the prospects for patients are very poor, with a survival duration of only a year on average.
Let's personalize your content